ES2544724T3 - Composición para tratar una hipertensión pulmonar - Google Patents
Composición para tratar una hipertensión pulmonar Download PDFInfo
- Publication number
- ES2544724T3 ES2544724T3 ES07855065.4T ES07855065T ES2544724T3 ES 2544724 T3 ES2544724 T3 ES 2544724T3 ES 07855065 T ES07855065 T ES 07855065T ES 2544724 T3 ES2544724 T3 ES 2544724T3
- Authority
- ES
- Spain
- Prior art keywords
- ambrisentane
- subjects
- initial level
- placebo
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 238000011282 treatment Methods 0.000 claims abstract description 146
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 52
- 238000003745 diagnosis Methods 0.000 claims abstract description 28
- 229960003310 sildenafil Drugs 0.000 claims abstract description 26
- 238000002648 combination therapy Methods 0.000 claims abstract description 20
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960000835 tadalafil Drugs 0.000 claims abstract description 12
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims abstract description 12
- 229960002381 vardenafil Drugs 0.000 claims abstract description 12
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 113
- 230000006872 improvement Effects 0.000 claims description 61
- 230000009467 reduction Effects 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 16
- 208000000059 Dyspnea Diseases 0.000 claims description 14
- 206010013975 Dyspnoeas Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 230000001746 atrial effect Effects 0.000 claims description 10
- 210000001147 pulmonary artery Anatomy 0.000 claims description 10
- 230000002685 pulmonary effect Effects 0.000 claims description 10
- 230000000004 hemodynamic effect Effects 0.000 claims description 8
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 208000019622 heart disease Diseases 0.000 claims description 5
- 230000009424 thromboembolic effect Effects 0.000 claims description 5
- 230000001732 thrombotic effect Effects 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 5
- 206010021133 Hypoventilation Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 206010025219 Lymphangioma Diseases 0.000 claims description 4
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 201000008298 histiocytosis Diseases 0.000 claims description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 4
- 230000000284 resting effect Effects 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 230000036593 pulmonary vascular resistance Effects 0.000 claims description 3
- 230000009547 development abnormality Effects 0.000 claims description 2
- 239000000902 placebo Substances 0.000 description 154
- 229940068196 placebo Drugs 0.000 description 154
- 239000003814 drug Substances 0.000 description 63
- 230000008859 change Effects 0.000 description 61
- 229940079593 drug Drugs 0.000 description 58
- 230000000694 effects Effects 0.000 description 33
- 230000036541 health Effects 0.000 description 32
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 description 28
- 230000007423 decrease Effects 0.000 description 24
- 238000011156 evaluation Methods 0.000 description 19
- 241000233805 Phoenix Species 0.000 description 18
- 230000002354 daily effect Effects 0.000 description 18
- 230000034994 death Effects 0.000 description 18
- 231100000517 death Toxicity 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 102400000686 Endothelin-1 Human genes 0.000 description 17
- 101800004490 Endothelin-1 Proteins 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 230000035558 fertility Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 206010039163 Right ventricular failure Diseases 0.000 description 13
- 230000002411 adverse Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 11
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 11
- 208000031886 HIV Infections Diseases 0.000 description 10
- 208000037357 HIV infectious disease Diseases 0.000 description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 210000000582 semen Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 8
- 206010030124 Oedema peripheral Diseases 0.000 description 8
- 229940028334 follicle stimulating hormone Drugs 0.000 description 8
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 8
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 7
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 7
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 229940127219 anticoagulant drug Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 230000004630 mental health Effects 0.000 description 7
- 230000037081 physical activity Effects 0.000 description 7
- 229940127293 prostanoid Drugs 0.000 description 7
- 150000003814 prostanoids Chemical class 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 6
- 108010073521 Luteinizing Hormone Proteins 0.000 description 6
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 description 6
- 102000003929 Transaminases Human genes 0.000 description 6
- 108090000340 Transaminases Proteins 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 239000002308 endothelin receptor antagonist Substances 0.000 description 6
- 108010067479 inhibin B Proteins 0.000 description 6
- 230000004199 lung function Effects 0.000 description 6
- 229940040129 luteinizing hormone Drugs 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 229940127291 Calcium channel antagonist Drugs 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 239000002830 appetite depressant Substances 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 229960001123 epoprostenol Drugs 0.000 description 5
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 229960003604 testosterone Drugs 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- 208000002330 Congenital Heart Defects Diseases 0.000 description 4
- 208000003287 Eisenmenger Complex Diseases 0.000 description 4
- 208000020686 Eisenmenger syndrome Diseases 0.000 description 4
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 4
- 208000015872 Gaucher disease Diseases 0.000 description 4
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 4
- 208000024799 Thyroid disease Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 208000028831 congenital heart disease Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229960003883 furosemide Drugs 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
- 208000007345 glycogen storage disease Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000000920 spermatogeneic effect Effects 0.000 description 4
- 238000010911 splenectomy Methods 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 239000003451 thiazide diuretic agent Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 102000010180 Endothelin receptor Human genes 0.000 description 3
- 108050001739 Endothelin receptor Proteins 0.000 description 3
- 102100040611 Endothelin receptor type B Human genes 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010019842 Hepatomegaly Diseases 0.000 description 3
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010036653 Presyncope Diseases 0.000 description 3
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 3
- 229960002414 ambrisentan Drugs 0.000 description 3
- 229960001523 chlortalidone Drugs 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000034737 hemoglobinopathy Diseases 0.000 description 3
- 229960002240 iloprost Drugs 0.000 description 3
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 239000002171 loop diuretic Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 208000007232 portal hypertension Diseases 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 201000002829 CREST Syndrome Diseases 0.000 description 2
- 208000029147 Collagen-vascular disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 208000020402 Enthesitis-related juvenile idiopathic arthritis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 108020001621 Natriuretic Peptide Proteins 0.000 description 2
- 102000004571 Natriuretic peptide Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000021060 Pulmonary arterial hypertension associated with another disease Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 2
- 229960002054 acenocoumarol Drugs 0.000 description 2
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 230000002891 anorexigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000027499 body ache Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004064 bumetanide Drugs 0.000 description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 2
- 230000001269 cardiogenic effect Effects 0.000 description 2
- 229960002155 chlorothiazide Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000011970 concomitant therapy Methods 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 229960004427 isradipine Drugs 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
- 229960002817 metolazone Drugs 0.000 description 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 2
- 239000000692 natriuretic peptide Substances 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000227 nisoldipine Drugs 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229960000989 perhexiline Drugs 0.000 description 2
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 238000011947 six minute walk test Methods 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 sulfonamide propanoic acid class Chemical class 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960005461 torasemide Drugs 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- ZGRIPYHIFXGCHR-UHFFFAOYSA-N 3-o-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-o-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C=1C=CC=2OCOC=2C=1C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCN(C)CC1=CC=C(F)C=C1 ZGRIPYHIFXGCHR-UHFFFAOYSA-N 0.000 description 1
- LTSOENFXCPOCHG-GQCTYLIASA-N 4-chloro-6-[[(e)-3-oxobut-1-enyl]amino]-1-n-prop-2-enylbenzene-1,3-disulfonamide Chemical compound CC(=O)\C=C\NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(=O)(=O)NCC=C LTSOENFXCPOCHG-GQCTYLIASA-N 0.000 description 1
- LBXHRAWDUMTPSE-AOOOYVTPSA-N 4-chloro-N-[(2S,6R)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide Chemical compound C[C@H]1CCC[C@@H](C)N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 LBXHRAWDUMTPSE-AOOOYVTPSA-N 0.000 description 1
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 description 1
- JDCJFONQCRLHND-UHFFFAOYSA-N 6-chloro-3-[(4-fluorophenyl)methyl]-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=C(F)C=C1 JDCJFONQCRLHND-UHFFFAOYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101100190268 Caenorhabditis elegans pah-1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 description 1
- VPMWFZKOWULPGT-UHFFFAOYSA-N Clorexolone Chemical compound C1C=2C=C(Cl)C(S(=O)(=O)N)=CC=2C(=O)N1C1CCCCC1 VPMWFZKOWULPGT-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 208000021066 Pulmonary arterial hypertension associated with connective tissue disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GYKFWCDBQAFCLJ-RTWAWAEBSA-N [(2s,3s)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 GYKFWCDBQAFCLJ-RTWAWAEBSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 229950007019 ambuside Drugs 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960004233 ancrod Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 description 1
- 229960002138 anisindione Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- NPUZIGSOEWMFKK-UHFFFAOYSA-N bromindione Chemical compound C1=CC(Br)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NPUZIGSOEWMFKK-UHFFFAOYSA-N 0.000 description 1
- 229950004502 bromindione Drugs 0.000 description 1
- HZIYHIRJHYIRQO-UHFFFAOYSA-N butazolamide Chemical compound CCCC(=O)NC1=NN=C(S(N)(=O)=O)S1 HZIYHIRJHYIRQO-UHFFFAOYSA-N 0.000 description 1
- 229950000426 butazolamide Drugs 0.000 description 1
- 229960005057 canrenone Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- JGMQLDDGSMLGDU-UHFFFAOYSA-M carboxymethylsulfanyl-[3-[(3-carboxy-2,2,3-trimethylcyclopentanecarbonyl)amino]-2-methoxypropyl]mercury Chemical compound [H+].[H+].[O-]C(=O)C[S-].COC(C[Hg+])CNC(=O)C1CCC(C)(C([O-])=O)C1(C)C JGMQLDDGSMLGDU-UHFFFAOYSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- IHJCXVZDYSXXFT-UHFFFAOYSA-N chloraminophenamide Chemical compound NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O IHJCXVZDYSXXFT-UHFFFAOYSA-N 0.000 description 1
- YRZQHIVOIFJEEE-UHFFFAOYSA-N chlorazanil Chemical compound NC1=NC=NC(NC=2C=CC(Cl)=CC=2)=N1 YRZQHIVOIFJEEE-UHFFFAOYSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229950000308 clentiazem Drugs 0.000 description 1
- 229960002883 clofenamide Drugs 0.000 description 1
- 229960004070 clopamide Drugs 0.000 description 1
- 229960005315 clorexolone Drugs 0.000 description 1
- 229960001307 clorindione Drugs 0.000 description 1
- NJDUWAXIURWWLN-UHFFFAOYSA-N clorindione Chemical compound C1=CC(Cl)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NJDUWAXIURWWLN-UHFFFAOYSA-N 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- BUCJFFQZPGTGPX-UHFFFAOYSA-N coumetarol Chemical compound C1=CC=C2OC(=O)C(C(C=3C(OC4=CC=CC=C4C=3O)=O)COC)=C(O)C2=C1 BUCJFFQZPGTGPX-UHFFFAOYSA-N 0.000 description 1
- ZGFASEKBKWVCGP-UHFFFAOYSA-N cyclocoumarol Chemical compound C12=CC=CC=C2OC(=O)C2=C1OC(OC)(C)CC2C1=CC=CC=C1 ZGFASEKBKWVCGP-UHFFFAOYSA-N 0.000 description 1
- 229950002423 cyclocoumarol Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- RCFKEIREOSXLET-UHFFFAOYSA-N disulfamide Chemical compound CC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(N)(=O)=O RCFKEIREOSXLET-UHFFFAOYSA-N 0.000 description 1
- 229950008177 disulfamide Drugs 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- LRMJAFKKJLRDLE-UHFFFAOYSA-N dotarizine Chemical compound O1CCOC1(C=1C=CC=CC=1)CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LRMJAFKKJLRDLE-UHFFFAOYSA-N 0.000 description 1
- 229950005624 dotarizine Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 229950010020 elgodipine Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- JCLHQFUTFHUXNN-UHFFFAOYSA-N ethyl biscoumacetate Chemical compound C1=CC=C2OC(=O)C(C(C=3C(OC4=CC=CC=C4C=3O)=O)C(=O)OCC)=C(O)C2=C1 JCLHQFUTFHUXNN-UHFFFAOYSA-N 0.000 description 1
- 229960004514 etozolin Drugs 0.000 description 1
- ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 229960002637 fenquizone Drugs 0.000 description 1
- DBDTUXMDTSTPQZ-UHFFFAOYSA-N fenquizone Chemical compound N1C=2C=C(Cl)C(S(=O)(=O)N)=CC=2C(=O)NC1C1=CC=CC=C1 DBDTUXMDTSTPQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005298 fluindione Drugs 0.000 description 1
- NASXCEITKQITLD-UHFFFAOYSA-N fluindione Chemical compound C1=CC(F)=CC=C1C1C(=O)C2=CC=CC=C2C1=O NASXCEITKQITLD-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 229950007692 lomerizine Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- IAYNHDZSSDUYHY-UHFFFAOYSA-N n-(2-acetyl-4,6-dimethylphenyl)-3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide Chemical compound CC(=O)C1=CC(C)=CC(C)=C1NC(=O)C1=C(S(=O)(=O)NC2=C(C(C)=NO2)C)C=CS1 IAYNHDZSSDUYHY-UHFFFAOYSA-N 0.000 description 1
- LFWCJABOXHSRGC-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C)C=N1 LFWCJABOXHSRGC-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229950006493 paraflutizide Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 208000004594 persistent fetal circulation syndrome Diseases 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229960001006 picotamide Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 230000010490 psychological well-being Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960003841 selexipag Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- QGGPRJRKWYRGKR-UHFFFAOYSA-M sodium;[3-[[2-(carboxylatomethoxy)benzoyl]amino]-2-methoxypropyl]mercury;hydrate Chemical compound O.[Na+].COC(C[Hg])CNC(=O)C1=CC=CC=C1OCC([O-])=O QGGPRJRKWYRGKR-UHFFFAOYSA-M 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- GUTZRTRUIMWMJZ-UHFFFAOYSA-N teclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)(Cl)Cl)NS2(=O)=O GUTZRTRUIMWMJZ-UHFFFAOYSA-N 0.000 description 1
- 229950009303 teclothiazide Drugs 0.000 description 1
- UISARWKNNNHPGI-UHFFFAOYSA-N terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
- 229960005383 terodiline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- UHLOVGKIEARANS-QZHINBJYSA-N tripamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN2C[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3C2)=C1 UHLOVGKIEARANS-QZHINBJYSA-N 0.000 description 1
- 229950004678 tripamide Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960000537 xipamide Drugs 0.000 description 1
- MTZBBNMLMNBNJL-UHFFFAOYSA-N xipamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C1=CC(S(N)(=O)=O)=C(Cl)C=C1O MTZBBNMLMNBNJL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86966706P | 2006-12-12 | 2006-12-12 | |
| US869667P | 2006-12-12 | ||
| PCT/US2007/087058 WO2008073928A1 (en) | 2006-12-12 | 2007-12-11 | Composition for treating a pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2544724T3 true ES2544724T3 (es) | 2015-09-03 |
Family
ID=39092031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07855065.4T Active ES2544724T3 (es) | 2006-12-12 | 2007-12-11 | Composición para tratar una hipertensión pulmonar |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US20080139593A1 (enExample) |
| EP (2) | EP2952193A1 (enExample) |
| JP (1) | JP2010512414A (enExample) |
| AU (1) | AU2007333115B2 (enExample) |
| CA (1) | CA2669536C (enExample) |
| CY (1) | CY2016017I2 (enExample) |
| DK (1) | DK2101777T3 (enExample) |
| ES (1) | ES2544724T3 (enExample) |
| HK (1) | HK1218393A1 (enExample) |
| HU (2) | HUE025355T2 (enExample) |
| LU (1) | LU93081I2 (enExample) |
| PL (1) | PL2101777T3 (enExample) |
| PT (1) | PT2101777E (enExample) |
| SI (1) | SI2101777T1 (enExample) |
| WO (1) | WO2008073928A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2544724T3 (es) | 2006-12-12 | 2015-09-03 | Gilead Sciences, Inc. | Composición para tratar una hipertensión pulmonar |
| CA2693400A1 (en) * | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| WO2010062640A1 (en) * | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| KR20130088834A (ko) * | 2010-06-30 | 2013-08-08 | 길리애드 사이언시즈, 인코포레이티드 | 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도 |
| ES2627944T3 (es) | 2010-10-15 | 2017-08-01 | Gilead Sciences, Inc. | Composiciones y métodos de tratamiento de hipertensión pulmonar |
| EP2741777B1 (en) * | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20130225595A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis |
| US20130224306A1 (en) * | 2012-02-29 | 2013-08-29 | Gilead Sciences, Inc. | Method for treating a pulmonary hypertension condition without companion diagnosis |
| WO2014003678A1 (en) * | 2012-06-28 | 2014-01-03 | Xspray Microparticles Ab | Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil |
| WO2015193889A1 (en) * | 2014-06-18 | 2015-12-23 | Sonivie Ltd. | Method for treating secondary pulmonary hypertension |
| US10576083B2 (en) * | 2015-08-13 | 2020-03-03 | Cipla (UK) Limited | Method of treating pulmonary arterial hypertension |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| SG11202000893QA (en) * | 2017-08-30 | 2020-02-27 | Bellerophon Pulse Tech Llc | Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease |
| EA202091286A1 (ru) * | 2017-12-28 | 2020-11-05 | Беллерофон Пульс Текнолоджис Ллс | Применение вдыхаемого оксида азота (ii) и кислорода для лечения легочной гипертензии |
| EP3965767A1 (en) * | 2019-05-06 | 2022-03-16 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
| RU2729033C1 (ru) * | 2020-02-03 | 2020-08-03 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования эффективности длительной специфической терапии у пациентов с идиопатической легочной гипертензией и неоперабельной хронической тромбоэмболической легочной гипертензией |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| EP3906928A1 (en) * | 2020-05-06 | 2021-11-10 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus |
| CN114324900A (zh) * | 2021-12-03 | 2022-04-12 | 上海市肺科医院 | 一种促卵泡激素的应用 |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
| AU2024207876A1 (en) * | 2023-01-09 | 2025-07-31 | Scpharmaceuticals Inc. | Methods of treatment using loop diuretics |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4325525A (en) | 1980-11-13 | 1982-04-20 | General Motors Corporation | Mounting member |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| DE4313412A1 (de) | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DK1174431T3 (da) | 1997-11-12 | 2012-08-20 | Bayer Pharma AG | 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2006007213A1 (en) * | 2004-06-23 | 2006-01-19 | Myogen, Inc. | Enoximone formulations and their use in the treatment of pde-iii mediated diseases |
| US20060205733A1 (en) * | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| TW200621261A (en) | 2004-08-26 | 2006-07-01 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| WO2006081289A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| SI2013208T1 (sl) * | 2006-04-21 | 2011-09-30 | Pfizer Prod Inc | Piridin(3,4-b)pirazinoni |
| EP2091539A1 (en) * | 2006-12-12 | 2009-08-26 | Gilead Colorado, Inc. | Ambrisentan combined with a renin inhibitor for hypertensive disorder |
| ES2544724T3 (es) * | 2006-12-12 | 2015-09-03 | Gilead Sciences, Inc. | Composición para tratar una hipertensión pulmonar |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| WO2010062640A1 (en) | 2008-10-28 | 2010-06-03 | Gilead Colorado, Inc. | Methods for treating idiopathic pulmonary fibrosis and associated complications |
| ES2627944T3 (es) | 2010-10-15 | 2017-08-01 | Gilead Sciences, Inc. | Composiciones y métodos de tratamiento de hipertensión pulmonar |
-
2007
- 2007-12-11 ES ES07855065.4T patent/ES2544724T3/es active Active
- 2007-12-11 EP EP15168201.0A patent/EP2952193A1/en not_active Withdrawn
- 2007-12-11 US US11/953,955 patent/US20080139593A1/en not_active Abandoned
- 2007-12-11 CA CA2669536A patent/CA2669536C/en active Active
- 2007-12-11 SI SI200731668T patent/SI2101777T1/sl unknown
- 2007-12-11 PL PL07855065T patent/PL2101777T3/pl unknown
- 2007-12-11 HU HUE07855065A patent/HUE025355T2/en unknown
- 2007-12-11 AU AU2007333115A patent/AU2007333115B2/en active Active
- 2007-12-11 WO PCT/US2007/087058 patent/WO2008073928A1/en not_active Ceased
- 2007-12-11 DK DK07855065.4T patent/DK2101777T3/en active
- 2007-12-11 JP JP2009541511A patent/JP2010512414A/ja not_active Withdrawn
- 2007-12-11 EP EP07855065.4A patent/EP2101777B1/en not_active Revoked
- 2007-12-11 PT PT78550654T patent/PT2101777E/pt unknown
-
2010
- 2010-02-17 US US12/706,818 patent/US20100152217A1/en not_active Abandoned
-
2011
- 2011-06-16 US US13/162,137 patent/US8377933B2/en active Active
-
2012
- 2012-12-21 US US13/723,758 patent/US20130116257A1/en not_active Abandoned
-
2014
- 2014-02-17 US US14/182,208 patent/US9474752B2/en active Active
-
2015
- 2015-04-24 US US14/695,775 patent/US9504685B2/en active Active
-
2016
- 2016-05-20 LU LU93081C patent/LU93081I2/fr unknown
- 2016-05-20 CY CY2016017C patent/CY2016017I2/el unknown
- 2016-05-20 HU HUS1600027C patent/HUS1600027I1/hu unknown
- 2016-06-06 HK HK16106422.7A patent/HK1218393A1/en unknown
- 2016-11-23 US US15/360,304 patent/US9993475B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150224100A1 (en) | 2015-08-13 |
| US8377933B2 (en) | 2013-02-19 |
| PL2101777T3 (pl) | 2015-10-30 |
| LU93081I2 (fr) | 2016-07-20 |
| CY2016017I1 (el) | 2016-10-05 |
| JP2010512414A (ja) | 2010-04-22 |
| EP2101777B1 (en) | 2015-05-20 |
| US9474752B2 (en) | 2016-10-25 |
| AU2007333115B2 (en) | 2013-01-10 |
| HUS1600027I1 (hu) | 2016-06-28 |
| US20080139593A1 (en) | 2008-06-12 |
| US20110245253A1 (en) | 2011-10-06 |
| WO2008073928A1 (en) | 2008-06-19 |
| EP2101777A1 (en) | 2009-09-23 |
| CA2669536C (en) | 2016-05-31 |
| US20130116257A1 (en) | 2013-05-09 |
| US20140296244A1 (en) | 2014-10-02 |
| US9993475B2 (en) | 2018-06-12 |
| US9504685B2 (en) | 2016-11-29 |
| HUE025355T2 (en) | 2016-02-29 |
| EP2952193A1 (en) | 2015-12-09 |
| CY2016017I2 (el) | 2016-10-05 |
| HK1218393A1 (en) | 2017-02-17 |
| CA2669536A1 (en) | 2008-06-19 |
| US20100152217A1 (en) | 2010-06-17 |
| AU2007333115A1 (en) | 2008-06-19 |
| SI2101777T1 (sl) | 2015-08-31 |
| US20170136016A1 (en) | 2017-05-18 |
| PT2101777E (pt) | 2015-09-18 |
| DK2101777T3 (en) | 2015-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2544724T3 (es) | Composición para tratar una hipertensión pulmonar | |
| US20140275094A1 (en) | Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis | |
| Olschewski et al. | Long-term therapy with inhaled iloprost in patients with pulmonary hypertension | |
| KR20130069855A (ko) | 폐 고혈압 치료의 조성물 및 방법 | |
| US20210267951A1 (en) | Combination therapy for pulmonary hypertension | |
| US20140030356A1 (en) | Method for treating a pulmonary hypertension condition without companion diagnosis | |
| WO2010062640A1 (en) | Methods for treating idiopathic pulmonary fibrosis and associated complications | |
| ES2309299T3 (es) | Tratamiento de la artritis reumatoide usando imatinib. | |
| JP2018521077A (ja) | 糖尿病性腎症を治療するためのｐｄｅ４阻害剤 | |
| KR20240134349A (ko) | 쇼그렌 증후군 또는 혼합결합조직병을 치료하기 위한 tlr7/8-길항제 | |
| RU2780758C2 (ru) | Комбинированная терапия легочной гипертензии |